Dr Sehn talks to ecancer at EHA 23 about combining polatuzumab vedotin, a novel antibody-drug conjugate, with bendamustine and rituximab for patients whose lmyphoma has returned. She outlines the design and construction of polatuzumab vedotin and...
Original Article: ADC polatuzumab vedotin in combinations for relapsed lymphoma